MLYS

Mineralys Therapeutics, Inc.

Price Chart

Latest Quote

$26.29

+0.68 (+2.66%)

Current Price

Previous Close	$25.61
Open	$25.61
Day High	$26.29
Day Low	$25.50
Volume	406,608

Fetched: 2026-06-24T16:35:13

Stock Information

Shares Outstanding	88.16M
Cash Equivalents	$646.06M
Net Income	$-151.78M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$2.27B
EPS (TTM)	$-1.97
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.47B
Income	$-151.78M
Book/sh	$7.74
Cash/sh	$7.33
Employees	76

Financial Ratios

Quick Ratio	43.90
Current Ratio	44.33

Returns & Margins

ROA	-21.27%
ROE	-30.99%

Ownership

Insider Ownership	0.66%
Institutional Ownership	109.59%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-12.30
P/B	3.33

Analyst Data

Recommendation	strong_buy
Target Price	$49.00

Technical Indicators

SMA20	$25.96
SMA50	$27.51
SMA200	$32.99
RSI	54.30
ATR	1.2646

Shares Float	60.37M
Short Float	13.95%
Short Ratio	7.87
Volatility	0.56
Rel Volume	0.65

Performance History

Week	+7.44%
Month	-13.65%
Quarter	+12.65%
6 Months	-30.02%
YTD	-27.82%
Year	+87.18%
3 Years	+63.65%
10 Years	+39.78%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$25.77	1,411,716
2026-06-23	$25.61	1,380,900
2026-06-22	$25.37	1,649,800
2026-06-18	$24.63	4,062,200
2026-06-17	$25.13	1,646,400
2026-06-16	$23.99	1,434,600
2026-06-15	$23.92	1,758,300
2026-06-12	$23.62	1,798,000
2026-06-11	$23.94	1,544,200
2026-06-10	$23.76	1,048,800
2026-06-09	$24.18	2,550,100
2026-06-08	$22.50	2,021,500
2026-06-05	$23.69	4,183,300
2026-06-04	$25.05	2,699,500
2026-06-03	$25.06	8,178,600
2026-06-02	$28.85	728,500
2026-06-01	$31.11	1,353,200
2026-05-29	$31.50	1,091,500
2026-05-28	$31.54	1,766,800
2026-05-27	$30.01	1,164,300
2026-05-26	$29.99	937,600

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

📰 Latest News

What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision

Motley Fool • 2026-06-23T21:39:01Z

Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock

Insider Monkey • 2026-06-17T18:29:04Z

Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat

Insider Monkey • 2026-06-11T10:20:32Z

Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New Data

Simply Wall St. • 2026-06-07T22:08:52Z

Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy

Insider Monkey • 2026-06-05T15:55:53Z

Mineralys Prices $150 Million Stock Offering, Repurchases Lorundrostat Royalty Obligations

MT Newswires • 2026-06-03T11:35:27Z

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Motley Fool • 2026-05-31T14:39:50Z

How FDA NDA Acceptance for Lorundrostat At Mineralys Therapeutics (MLYS) Has Changed Its Investment Story

Simply Wall St. • 2026-05-11T15:12:36Z

Mineralys Therapeutics Q1 Earnings Call Highlights

MarketBeat • 2026-05-07T03:06:36Z

Mineralys Therapeutics, Inc. Q1 2026 Earnings Call Summary

Moby • 2026-05-07T00:30:04Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$170,604,000	$192,403,000	$84,657,000	$31,479,000
Net Non Operating Interest Income Expense	$15,953,000	$14,588,000	$12,756,000	$1,676,000
Operating Expense	$170,604,000	$192,403,000	$84,657,000	$31,479,000
General And Administrative Expense	$38,595,000	$23,822,000	$14,296,000	$5,229,000
Other Income Expense	-	$5,000	$3,000	$4,000
Other Non Operating Income Expenses	-	$5,000	$3,000	$4,000
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Net Interest Income	$15,953,000	$14,588,000	$12,756,000	$1,676,000
Interest Income	$15,953,000	$14,588,000	$12,756,000	$1,676,000
Normalized Income	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Net Income From Continuing And Discontinued Operation	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Total Operating Income As Reported	$-170,604,000	$-192,403,000	$-84,657,000	$-31,479,000
Net Income Common Stockholders	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Net Income	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Net Income Including Noncontrolling Interests	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Net Income Continuous Operations	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Pretax Income	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Interest Income Non Operating	$15,953,000	$14,588,000	$12,756,000	$1,676,000
Operating Income	$-170,604,000	$-192,403,000	$-84,657,000	$-31,479,000
Per Share
Diluted EPS	$-2.29	$-3.66	$-1.99	$-0.76
Basic EPS	$-2.29	$-3.66	$-1.99	$-0.76
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-170,545,000	$-192,360,000	$-84,657,000	$-31,479,000
Reconciled Depreciation	$59,000	$43,000	$0	-
EBITDA (Bullshit earnings)	$-170,545,000	$-192,360,000	$-84,657,000	$-31,479,000
EBIT	$-170,604,000	$-192,403,000	$-84,657,000	$-31,479,000
Diluted Average Shares	$67,656,355	$48,539,795	$36,188,254	$39,056,653
Basic Average Shares	$67,656,355	$48,539,795	$36,188,254	$39,056,653
Diluted NI Availto Com Stockholders	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Research And Development	$132,009,000	$168,581,000	$70,361,000	$26,250,000
Selling General And Administration	$38,595,000	$23,822,000	$14,296,000	$5,229,000
Other Gand A	$38,595,000	$23,822,000	$14,296,000	$5,229,000
Total Unusual Items	-	-	-	-
Total Unusual Items Excluding Goodwill	-	-	-	-
Otherunder Preferred Stock Dividend	-	-	-	-
Gain On Sale Of Security	-	-	-	-

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$646,693,000	$191,257,000	$241,154,000	$-52,269,000
Total Assets	$661,806,000	$205,903,000	$251,636,000	$114,442,000
Total Non Current Assets	$420,000	$552,000	$2,533,000	$1,631,000
Other Non Current Assets	$382,000	$499,000	$51,000	-
Current Assets	$661,386,000	$205,351,000	$249,103,000	$112,811,000
Other Current Assets	$4,751,000	$7,164,000	$12,536,000	$2,701,000
Cash Cash Equivalents And Short Term Investments	$656,635,000	$198,187,000	$236,567,000	$110,110,000
Cash And Cash Equivalents	$172,921,000	$114,091,000	$49,304,000	$87,701,000
Cash Equivalents	$171,891,000	$113,427,000	$48,661,000	$84,829,000
Cash Financial	$1,030,000	$664,000	$643,000	$2,872,000
Non Current Deferred Assets	-	-	$51,000	$1,631,000
Prepaid Assets	-	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$15,113,000	$14,646,000	$10,482,000	$166,711,000
Total Non Current Liabilities Net Minority Interest	$0	$0	$0	$158,644,000
Current Liabilities	$15,113,000	$14,646,000	$10,482,000	$8,067,000
Payables And Accrued Expenses	$9,573,000	$11,064,000	$8,883,000	$7,402,000
Payables	$2,017,000	$479,000	$601,000	$1,907,000
Accounts Payable	$2,017,000	$479,000	$601,000	$1,907,000
Equity
Common Stock Equity	$646,693,000	$191,257,000	$241,154,000	$-52,269,000
Total Equity Gross Minority Interest	$646,693,000	$191,257,000	$241,154,000	$-52,269,000
Stockholders Equity	$646,693,000	$191,257,000	$241,154,000	$-52,269,000
Retained Earnings	$-457,169,000	$-302,518,000	$-124,708,000	$-52,810,000
Preferred Securities Outside Stock Equity	-	$0	$0	$158,644,000
Preferred Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$81,536,557	$49,821,915	$41,133,916	$39,056,653
Share Issued	$81,536,557	$49,821,915	$41,133,916	$39,056,653
Tangible Book Value	$646,693,000	$191,257,000	$241,154,000	$-52,269,000
Invested Capital	$646,693,000	$191,257,000	$241,154,000	$-52,269,000
Working Capital	$646,273,000	$190,705,000	$238,621,000	$104,744,000
Total Capitalization	$646,693,000	$191,257,000	$241,154,000	$-52,269,000
Additional Paid In Capital	$1,103,854,000	$493,770,000	$365,858,000	$540,000
Capital Stock	$8,000	$5,000	$4,000	$1,000
Common Stock	$8,000	$5,000	$4,000	$1,000
Pensionand Other Post Retirement Benefit Plans Current	$5,540,000	$3,582,000	$1,599,000	$665,000
Current Accrued Expenses	$7,556,000	$10,585,000	$8,282,000	$5,495,000
Net PPE	$38,000	$53,000	$0	-
Other Short Term Investments	$483,714,000	$84,096,000	$187,263,000	$22,409,000
Investments And Advances	-	$0	$2,482,000	$0
Other Investments	-	$0	$2,482,000	$0
Preferred Stock	-	-	-	-

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-142,431,000	$-166,410,000	$-81,173,000	$-29,221,000
Operating Activities
Operating Cash Flow	$-142,416,000	$-166,314,000	$-81,173,000	$-29,221,000
Cash Flow From Continuing Operating Activities	$-142,416,000	$-166,314,000	$-81,173,000	$-29,221,000
Investing Activities
Capital Expenditure	$-15,000	$-96,000	-	-
Investing Cash Flow	$-389,753,000	$114,959,000	$-160,472,000	$-21,759,000
Cash Flow From Continuing Investing Activities	$-389,753,000	$114,959,000	$-160,472,000	$-21,759,000
Financing Activities
Issuance Of Capital Stock	$578,361,000	$116,059,000	$202,990,000	$129,648,000
Financing Cash Flow	$590,999,000	$116,142,000	$203,248,000	$128,019,000
Cash Flow From Continuing Financing Activities	$590,999,000	$116,142,000	$203,248,000	$128,019,000
Net Other Financing Charges	$-391,000	$-435,000	-	$-1,629,000
Net Common Stock Issuance	$578,361,000	$116,059,000	$202,990,000	$-1,629,000
Common Stock Issuance	$578,361,000	$116,059,000	$202,990,000	-
Net Preferred Stock Issuance	-	-	$0	$129,648,000
Preferred Stock Issuance	-	-	$0	$129,648,000
Repurchase Of Capital Stock	-	-	-	$-1,629,000
Other
End Cash Position	$172,921,000	$114,091,000	$49,304,000	$87,701,000
Beginning Cash Position	$114,091,000	$49,304,000	$87,701,000	$10,662,000
Changes In Cash	$58,830,000	$64,787,000	$-38,397,000	$77,039,000
Proceeds From Stock Option Exercised	$13,029,000	$518,000	$258,000	$0
Net Investment Purchase And Sale	$-389,738,000	$115,055,000	$-160,472,000	$-21,759,000
Sale Of Investment	$425,000,000	$488,500,000	$187,500,000	$50,000,000
Purchase Of Investment	$-814,738,000	$-373,445,000	$-347,972,000	$-71,759,000
Net PPE Purchase And Sale	$-15,000	$-96,000	$0	-
Purchase Of PPE	$-15,000	$-96,000	$0	-
Change In Working Capital	$2,731,000	$9,522,000	$-7,470,000	$772,000
Change In Payables And Accrued Expense	$427,000	$4,163,000	$2,415,000	$3,012,000
Change In Prepaid Assets	$2,470,000	$4,935,000	$-9,530,000	$-2,240,000
Change In Receivables	$-166,000	$424,000	$-355,000	$0
Other Non Cash Items	$-9,879,000	$-9,405,000	$-6,865,000	$-649,000
Stock Based Compensation	$19,324,000	$11,336,000	$5,060,000	$455,000
Depreciation Amortization Depletion	$59,000	$43,000	$0	-
Depreciation And Amortization	$59,000	$43,000	$0	-
Net Income From Continuing Operations	$-154,651,000	$-177,810,000	$-71,898,000	$-29,799,000
Common Stock Payments	-	-	-	$-1,629,000
Issuance Of Debt	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Short Term Debt Issuance	-	-	-	-
Short Term Debt Issuance	-	-	-	-
Unrealized Gain Loss On Investment Securities	-	-	-	-

Fetched: 2026-06-22